Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial) CIRCULATION Chi, G., Yee, M. K., Amin, A. N., Goldhaber, S. Z., Hernandez, A. F., Hull, R. D., Cohen, A. T., Harrington, R. A., Gibson, C. 2018; 137 (1): 91–94

View details for PubMedID 29279341